Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegc...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Annals of hematology Ročník 101; číslo 9; s. 1971 - 1986
Hlavní autoři:	Wong, Raymond S. M., Pullon, Humphrey W. H., Amine, Ismail, Bogdanovic, Andrija, Deschatelets, Pascal, Francois, Cedric G., Ignatova, Kalina, Issaragrisil, Surapol, Niparuck, Pimjai, Numbenjapon, Tontanai, Roman, Eloy, Sathar, Jameela, Xu, Raymond, Al-Adhami, Mohammed, Tan, Lisa, Tse, Eric, Grossi, Federico V.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2022 Springer Nature B.V
Témata:	Adult Anemia Biomarkers Blood diseases Bone marrow Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Complement Inactivating Agents - adverse effects Dehydrogenases Drug dosages FDA approval Hematology Hemoglobin Hemoglobins Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Hospitals Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Original Article Peptides, Cyclic - adverse effects Pharmaceuticals Quality of life Hemoglobin LDH Phase I/II trials Safety Paroxysmal nocturnal hemoglobinuria (PNH) Quality of life
ISSN:	0939-5555, 1432-0584, 1432-0584
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!